Cancer trial tests drug combo to keep leukemia at bay
NCT ID NCT02007044
Summary
This study aims to find out if adding the immunotherapy drug rituximab to the cancer drug ibrutinib works better than ibrutinib alone for adults whose chronic lymphocytic leukemia has returned after prior treatment. It will compare how long patients stay cancer-free on each regimen and monitor side effects. The goal is to improve long-term control of the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROLYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.